XL-protein GmbH
Lise-Meitner-Str. 30
85354 Freising
Germany
Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-mail: info@xl-protein.com
Web: www.xl-protein.com
Corporate overview
XL-protein is a privatly owned German biotech company commercializing the revolutionary 'PASylation' technology, which allows the extension of the plasma half-life of biopharmaceuticals. With its strong proprietary technology position, including a broad basis of preclinical data, XL-protein will focus at the preclinical as well clinical development of PASylated proteins in several disease areas.
XL-protein's goal is to provide improved second generation biopharma-ceuticals allowing lessfrequent and lower dosing together with better tolerability, thus making treatment cheaper and supporting patient compliance and safety.
XL-protein was founded in 2009 as a spin-off from the Insitute of Biological Chemistry at the Technische Universität München (TUM). The company is located at Freising-Weihenstephan, well situated in the neighbourhood of the Munich international airport as well as the TUM life science campus.
